French Observatory of Rare Malignant Tumors of the Ovary
NCT01304043 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 204
Last updated 2012-04-20
Summary
To take charge of the treatment in rare adult ovarian tumors with an homogenous manner (germinal and sexual cords tumors), at different stages of the disease.
Conditions
- Ovarian Tumors
Interventions
- DRUG
-
chemotherapies protocols
Cisplatine 20 mg/m² IV Etoposide 100 mg/m² IV Bléomycine 30 mg IV
Sponsors & Collaborators
-
ARCAGY/ GINECO GROUP
lead OTHER
Principal Investigators
-
Isabelle Ray-Coquard, Physician · GINECO
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2002-01-31
- Completion
- 2011-06-30
Countries
- France
Study Locations
More Related Trials
-
Constitution of ex Vivo Ovarian Tumor Models for the Validation of the Interest of Innovative Therapies and the Search for Tumor or Circulating Biomarkers Predictive of Treatment Response
NCT03831230 ·Status: COMPLETED
-
Chemoresistance of Trophoblastic Tumors
NCT03488901 ·Status: UNKNOWN
-
Unravelling Tumour Biology In Ovarian Cancer With Precision Imaging
NCT06084195 ·Status: RECRUITING ·Phase: NA
-
Platino-resistance in Ovarian Cancer
NCT03954171 ·Status: RECRUITING ·Phase: NA
-
Study of Circulating Tumoral DNA in Ovarian Cancer
NCT01350908 ·Status: COMPLETED ·Phase: NA
-
Prognostic and Predictive Biomarkers in Ovarian Cancers
NCT03010124 ·Status: RECRUITING ·Phase: NA
-
A Study of ABT-263 as Single Agent in Women With Platinum Resistant/Refractory Recurrent Ovarian Cancer
NCT02591095 ·Status: COMPLETED ·Phase: PHASE2
-
Intraperitoneal Hyperthermic Chemotherapy in Epithelial Ovarian Carcinoma
NCT00349505 ·Status: UNKNOWN ·Phase: PHASE2
-
Use of FACT-GOG/NTX Questionnaire in Peripheral Neurotoxicity & Validation of a French Version of This Questionnaire
NCT00517621 ·Status: COMPLETED ·Phase: PHASE2
-
Observational Retrospective Study on Treatment and Outcomes in Patients With Low-grade Serous Ovarian Cancer
NCT02408536 ·Status: UNKNOWN
-
Study Comparing Tumor Debulking Surgery Versus Chemotherapy Alone in Recurrent Platinum-Sensitive Ovarian Cancer
NCT01166737 ·Status: COMPLETED ·Phase: NA
-
CINSARC Genomic Signature as Predictor of Resectability of Ovarian Adenocarcinoma
NCT04248231 ·Status: COMPLETED
-
Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer
NCT06907771 ·Status: RECRUITING
-
Living After a Rare Cancer of the Ovary: Chronic Fatigue, Quality of Life and Late Effects of Chemotherapy
NCT03418844 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Breast Cancer After Ovarian Cancer During and/or After Therapy: Genomic Evaluation
NCT05763472 ·Status: UNKNOWN
-
Patients Derived Organoids in Ovarian Cancer
NCT06085404 ·Status: RECRUITING ·Phase: NA
-
Genomic Profiling of the Residual Disease of Advanced-stage Ovarian Cancer After Neoadjuvant Chemotherapy
NCT03491033 ·Status: COMPLETED
-
Individualized Precision Treatment Based on Ovarian Cancer Organoid Model
NCT05813509 ·Status: UNKNOWN ·Phase: NA
-
Ovarian Cancer Treatment Platinum-sensitive Relapse - Cohort Study (PROSPECTYON)
NCT02163720 ·Status: COMPLETED
-
Cytoreductive Surgery and HIPEC in First or Secondary Platinum-resistant Recurrent Ovarian Epithelial Cancer
NCT03220932 ·Status: UNKNOWN ·Phase: PHASE3
-
Taxol Carboplatin and Erythropoetin
NCT00158379 ·Status: COMPLETED ·Phase: PHASE2
-
Role of Surgery in Advanced Ovarian Cancer
NCT03980028 ·Status: COMPLETED
-
Real-life Data of Olaparib in Relapsed Ovarian Cancers Patients
NCT04152941 ·Status: COMPLETED
-
The Culture of Advanced or Recurrent Ovarian Cancer Organoids and Drug Screening
NCT05290961 ·Status: UNKNOWN
-
Prospective Clinico-biological Database of Patients With Ovarian and/or Peritoneal and/or Fallopian Tube Carcinoma
NCT06969833 ·Status: RECRUITING ·Phase: NA